• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Diatech changes name to Diatide

Article

Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of

Peptide radiopharmaceutical developer Diatech has changed itsname to Diatide in a move designed to link itself more closelyto the technology it is developing. The Londonderry, NH-basedcompany announced the change this month after approval by itsboard of directors.

Diatide is developing peptide-based imaging and therapy agentsthat are labeled with technetium-99m (SCAN 8/30/95). The firmplans to file a new drug application in 1997 for its lead product,an agent for the detection of deep vein thrombosis.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.